LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy.
Ning S, Armstrong CM, Xing E, Leslie AR, Gao RY, Sharifi M, Schaaf ZA, Lou W, Han X, Xu DH, Yang R, Cheng J, Mohammed S, Mitsiades N, Liu C, Lombard AP, Wu CY, Cheng X, Li PK, Gao AC.
Ning S, et al. Among authors: li pk.
Cancer Res. 2024 Nov 4;84(21):3617-3628. doi: 10.1158/0008-5472.CAN-24-0440.
Cancer Res. 2024.
PMID: 39088701